BMD 2341

Drug Profile

BMD 2341

Alternative Names: BMD 2341

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arkansas System
  • Developer BiologicsMD
  • Class Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia

Most Recent Events

  • 26 Apr 2016 Preclinical trials in Alopecia in USA (Topical)
  • 28 Jul 2015 BiologicsMD has patent protection for BMD 2341 in USA
  • 01 Jan 2008 BiologicsMD has pending PCT patent applications related to PTH-CBD™
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top